What are Indivior Pharmaceuticals, Inc. 's profit margins?

Gross margin is 81.3% and operating margin is 25.8%, with a 19.4% net margin.

Where does Indivior Pharmaceuticals, Inc. 's income statement data come from?

Every line is extracted from Indivior Pharmaceuticals, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Indivior Pharmaceuticals, Inc. INDV Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Total revenue	$317M-11.5%	$358M+14.0%	$314M+4.0%	$302M+13.5%	$266M-11.0%
Total cost of revenue	$40M-40.3%	$67M-19.3%	$83M+59.6%	$52M+18.2%	$44M-8.3%
Gross profit	$277M-4.8%	$291M+26.0%	$231M-7.6%	$250M+12.6%	$222M-11.6%
Gross margin	87.4%+6.1pp	81.3%+7.7pp	73.6%-9.2pp	82.8%-0.7pp	83.5%-0.5pp
Research and development	$16M-23.8%	$21M-36.4%	$33M+57.1%	$21M-4.5%	$22M-29.0%
Selling, general and administrative	$124M-34.4%	$189M+21.9%	$155M-1.9%	$158M+18.8%	$133M-24.0%
Other operating expenses	$139M—	——	$187M—	——	$156M-23.9%
Total operating expenses	$139M—	——	$187M—	——	$156M-23.9%
Operating income	$137M+69.1%	$81M+88.4%	$43M-40.3%	$72M+9.1%	$66M+43.5%
Operating margin	43.2%+20.6pp	22.6%+8.9pp	13.7%-10.1pp	23.8%-1.0pp	24.8%+9.4pp
Interest expense	$7M+16.7%	$6M-50.0%	$12M-20.0%	$15M+25.0%	$12M-7.7%
Interest income	$3M-50.0%	$6M0.0%	$6M0.0%	$6M+50.0%	$4M-20.0%
Gain (loss) on extinguishment of debt	-$18M—	——	——	——	$0—
Income before income taxes	$115M+42.0%	$81M+119%	$37M-40.3%	$62M+5.1%	$59M+55.3%
Income tax expense	$26M—	——	-$5M-111%	$44M+300%	$11M-35.3%
Net income	$89M-12.7%	$102M+143%	$42M+133%	$18M-61.7%	$47M+124%
Net margin	28.1%-0.4pp	28.5%+15.1pp	13.4%+7.4pp	6%-11.7pp	17.7%+10.6pp
Diluted earnings per share	$0.69-12.7%	$0.79+139%	$0.33+136%	$0.14-63.2%	$0.38+138%
Basic earnings per share	$0.71-12.3%	$0.81+138%	$0.34+127%	$0.15-60.5%	$0.38+138%
Weighted-average shares, diluted	129M+0.8%	128M-0.8%	129M+2.4%	126M+0.8%	125M-6.0%
Weighted-average shares, basic	124M-0.8%	125M0.0%	125M0.0%	125M+0.8%	124M-6.1%
Research and development expense	$16M-23.8%	$21M-36.4%	$33M+57.1%	$21M-4.5%	$22M-29.0%
Revenue From Contract With Customer Excluding Assessed Tax	$317M-11.5%	$358M+14.0%	$314M+4.0%	$302M+13.5%	$266M-11.0%
EBIT	$137M+69.1%	$81M+88.4%	$43M-40.3%	$72M+9.1%	$66M+43.5%
EBITDA	$139M+67.5%	$83M+80.4%	$46M-37.8%	$74M+7.2%	$69M+35.3%
EBITDA	$139M+67.5%	$83M+80.4%	$46M-37.8%	$74M+7.2%	$69M+35.3%
EBITDA margin	43.8%+20.7pp	23.2%+8.5pp	14.6%-9.9pp	24.5%-1.4pp	25.9%+8.9pp
EBIT	$137M+69.1%	$81M+88.4%	$43M-40.3%	$72M+9.1%	$66M+43.5%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Indivior Pharmaceuticals, Inc. 's profit margins?: Gross margin is 81.3% and operating margin is 25.8%, with a 19.4% net margin.
Where does Indivior Pharmaceuticals, Inc. 's income statement data come from?: Every line is extracted from Indivior Pharmaceuticals, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.